Merck (MRK) is back in the spotlight after securing FDA approval for LIPFENDRA, the first oral PCSK9 inhibitor for lowering LDL cholesterol, alongside fresh plans to widen access to its investigational HIV PrEP pill, alimatravir.
See our latest analysis for Merck.
Merck’s recent updates around LIPFENDRA and alimatravir come as the stock trades at US$130.48, with a 30-day share price return of 9.1% and year-to-date share price return of 22.6%, while the 1-year total shareholder return of 60.3% points to strong, sustained momentum.
If breakthroughs in cardiovascular and HIV treatments have your attention, it could be a good moment to see what else is emerging across 39 healthcare AI stocks
After a 60.3% 1-year total return and fresh product headlines, Merck now trades only about 3% below the average analyst target, but at roughly a 40% discount to one intrinsic value estimate. Is the market’s caution misplaced?
Most Popular Narrative: 2% Undervalued
Merck’s most followed narrative pegs fair value at about $132.78, only slightly above the $130.48 last close. This puts a sharper focus on the assumptions behind that gap.
The analysts have a consensus price target of $132.78 for Merck based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $155.0, and the most bearish reporting a price target of just $100.0.
Wondering what earnings curve, margin profile and valuation multiple have to line up for this fair value to make sense? The narrative describes a detailed path from today’s profit base to a larger earnings pool and a different P/E framework, along with explicit assumptions about how long that shift could take.
Result: Fair Value of $132.78 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Merck’s story could look different if pricing pressure from Medicare negotiations bites harder than expected, or if KEYTRUDA’s loss of exclusivity hits revenue harder than modeled.
Find out about the key risks to this Merck narrative.
Another View: Merck Looks Expensive On Earnings
While the analyst narrative and our cash flow estimate suggest Merck could be undervalued, the current P/E of 36.1x tells a different story. That compares with 15x for the US Pharmaceuticals industry, 27x for peers, and a fair ratio of 36x, which leaves little room for error.
Put simply, Merck already trades at a premium to both its sector and similar companies, with only a very small gap to the fair ratio. For investors who care about entry price, this may raise the question of whether to be patient or to wait for earnings to move closer to the current valuation.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If Merck’s mixed signals on value, growth and risk leave you undecided, this is the moment to review the details quickly and shape your own view with 2 key rewards and 4 important warning signs
Looking for more investment ideas beyond Merck?
If Merck has sharpened your focus on quality, do not stop here. Broaden your watchlist with fresh ideas that could fit different roles in your portfolio.
- Target potential mispricings by scanning companies that combine quality fundamentals with appealing valuations through the 38 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies highlighted in the 7 dividend fortresses that offer higher yields with a focus on resilience.
- Reduce portfolio stress by checking stocks filtered in the 79 resilient stocks with low risk scores that score well on financial stability and risk measures.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com